Identification

Name
Nicorandil
Accession Number
DB09220
Type
Small Molecule
Groups
Approved
Description

Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment ith other antianginal drugs [10]. Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325].

Structure
Thumb
Synonyms
  • 2-Nicotinamidoethyl nitrate
  • BRN 0481451
  • N-(2-Hydroxyethyl)nicotinamide nitrate
  • N-(2-Hydroxyethyl)nicotinamide nitrate (ester)
  • Nicorandilum
  • SG-75
External IDs
SG-75
International/Other Brands
Adancor (Merck) / Angedil (Egis Pharmaceuticals) / Angicor (Sanofi-Aventis) / Aprior (OEP Phils) / Av-Cor (Strides Arcolab) / Corangi (Unimed & Unihealth) / Cordinik (PIQ-Farma) / Corflo (Wockhardt) / Dancor (Merck) / Ikorel (Sanofi) / Ikotril (Sanofi-aventis) / K-Cor (Macleods) / Nicodil (Genovate) / Nicoduce (AHPL) / Nicolan (G.L. Pharma) / Nicoline (Johnlee) / Nicor (Orion) / Nicoral (General Pharma) / Nicostar (Lupin) / Nidil (Shou Chan) / Nikoran (Torrent) / Nikoranmart (Towa Yakuhin) / Nirandil (Standard) / Randil (Adwia) / Sigmart (Chugai) / Silvinol (Nisshin Pharmaceutical) / Zynicor (Zydus)
Categories
UNII
260456HAM0
CAS number
65141-46-0
Weight
Average: 211.177
Monoisotopic: 211.059305782
Chemical Formula
C8H9N3O4
InChI Key
LBHIOVVIQHSOQN-UHFFFAOYSA-N
InChI
InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
IUPAC Name
2-[(pyridin-3-yl)formamido]ethyl nitrate
SMILES
[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1

Pharmacology

Indication

Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.

Structured Indications
Not Available
Pharmacodynamics

Nicorandil is a potassium channel opener with nitrovasodilator (NO donor) actions, making it both an arterial and a venous dilator [10]. It causes sustained dilation of both the arterial resistance and conductive vessels that increases coronary blood flow, however the effect of the drug on coronary arteries does not involve the coronary steal phenomenon [11]. Activation of potassium channels lead to hyperpolarization of the smooth muscle cells, followed by arterial dilation and afterload reduction. Nicorandil is shown to increase pooling in the capacitance vessels with a decrease in preload through relaxing the venous vascular system. Overall, improved blood flow and reduced infarct size are achieved through reduction of end-diastolix pressure and decreased extravascular component of vascular resistance [11]. Open studies showed the effectiveness of nicorandil treatment on various types of angina pectoris [8].

Mechanism of action

Nicorandil mediates its therapeutic efficacy via two main mechanisms. Nicorandil is an activator and opener of ATP-sensitive (ATP-dependent) potassium channels (KATP channels) that are composed of Kir6.x-type subunits and sulfonylurea receptor (SUR) subunits. Nicorandil binding sites are located in the sulfonylurea receptor 2 (SUR2) in the ATP-sensitive potassium channel [4], which are regulatory subunits of the channel that exhibit an ATPase activitiy [2]. There are 2 types of SUR2 subunits (2A/2B) that have identical nucleotide binding domains (NBD), where SUR2A is more predominantly expressed in skeletal and cardiac myocytes and SUR2B in smooth muscle cells [2]. Nicorandil more potently activates SUR2B/Kir6.2 than SUR2A/Kir6.2 channels to cause hyperpolarization. ATP-NBD1 interaction influences the channel signalling by nicorandil, and the response of the channel to nicorandil is also facilitated and heightened by the interaction of ATP or ADP with NBD2 [3]. Potentiated activity of ATP-sensitive channels have cardioprotective role by limiting the duration of action potentials and preventing intraceullar calcium overload [7]. This attenuates cellular injury by preserving cellular energetics and ultimately cell survival [6]. KATP channel-dependent membrane hyperpolarization can also lead to vasodilation via reduction in Ca2+ influx through the voltage-gated Ca2+ channels and regulation of intracellular Ca2+ mobilization in smooth muscle cells [6]. Nicorandil contain a nitrate moiety in its structure, making it a good dilator of vascular smooth muscle like other nitroglycerin esters [5]. Direct relaxation of venous vascular system arises from NO-donor mediated stimulation of guanylyl cyclase and increased levels of intracellular cyclic GMP (cGMP). Elevated levels of cGMP contributes to the total relaxing effect of nicorandil at higher concentrations of the drug [1].

TargetActionsOrganism
AATP-binding cassette sub-family C member 9
activator
Human
Absorption

Following oral administration, nicorandil is well absorbed from the gastrointestinal tract with the oral bioavailability of 75% with the maximum peak plasma concentration (Cmax) reached within 30-60 minutes. The mean Cmax is Cmax then is approximately 300 ng/ml [9]. Steady-state plasma concentrations of nicorandil usually are reached within approximately 96-120 h after twice daily dosing (10 or 20mg) [11].

Volume of distribution

After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0-1.4 L/kg body weight [9].

Protein binding

Nicorandil is about 25% bound to human albumin and other plasma proteins [9].

Metabolism

Nicorandil undergoes extensive hepatic metabolism [11]. The main biotransformation pathways of nicorandil are denitration, followed by subsequent nicotinamide metabolism. The main pharmacologically inactive denitrated metabolite 2-nicotinamidoethanol can be detected in the urine. The derivatives formed from the nicotinamide metabolism of denitrated products are nicotinuric acid, nicotinamide, N-methylnicotinamide and nicotinic acid [11].

Route of elimination

The main route of elimination is the kidney with more than 60% of the administered dose was eliminated in the urine 24 hours after dosing [11]. Only approximately 1% of nicorandil is excreted unchanged in the urine, and the remaining compounds are mainly the denitrated metabolite (9%) and its derivatives (e.g. nicotinuric acid 6%, nicotinamide 1%, N-methylnicotinamide < 1% and nicotinic acid < 1%) [11]. Less than 2% of administered dose is excreted through the biliary system [9].

Half life

The elimination half life is approximately 1 hour [9].

Clearance

The total body clearance is approximately 1.15 L/min [9].

Toxicity

Common adverse effects include lethargy, back pain, chest pain, infection, feeling of weakness. In the cardiovascular system, hypotension, increased heart rate in higher doses, palpitations, worsened angina pectoris and vasodilation/flush may be observed. Dyspepsia, nausea, and vomiting may occur as gastrointestinal disorders. Headaches may arise from vasodilation. Other common side effects include myalgia, bronchitis, dyspnoea, and respiratory disorder [11]. Nicorandil does not affect fertility of male or female rats, and shows no potential in carcinogenic, mutagenic or genotoxic studies [11]. Oral LD50 values in mouse, rat and dog are 626 mg/kg, 1220 mg/kg and 62.5 mg/kg, respectively [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Nicorandil.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Nicorandil.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nicorandil.Experimental
AcebutololNicorandil may increase the hypotensive activities of Acebutolol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nicorandil.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Nicorandil.Approved
AldesleukinNicorandil may increase the hypotensive activities of Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nicorandil.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Nicorandil.Approved, Investigational
AliskirenNicorandil may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nicorandil.Approved, Withdrawn
AmbrisentanNicorandil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nicorandil.Approved
AmifostineNicorandil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideNicorandil may increase the hypotensive activities of Amiloride.Approved
AmineptineAmineptine may increase the hypotensive activities of Nicorandil.Illicit, Withdrawn
AmiodaroneNicorandil may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the hypotensive activities of Nicorandil.Approved
AmlodipineNicorandil may increase the hypotensive activities of Amlodipine.Approved
Amphotericin BNicorandil may increase the hypotensive activities of Amphotericin B.Approved, Investigational
Amyl NitriteNicorandil may increase the hypotensive activities of Amyl Nitrite.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Nicorandil.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Nicorandil.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Nicorandil.Investigational
ApomorphineNicorandil may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineNicorandil may increase the hypotensive activities of Apraclonidine.Approved
ArotinololNicorandil may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideNicorandil may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Nicorandil.Investigational
AtenololNicorandil may increase the hypotensive activities of Atenolol.Approved
Azilsartan medoxomilNicorandil may increase the hypotensive activities of Azilsartan medoxomil.Approved
BarnidipineNicorandil may increase the hypotensive activities of Barnidipine.Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nicorandil.Approved, Investigational
BenazeprilNicorandil may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideNicorandil may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nicorandil.Withdrawn
BepridilNicorandil may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nicorandil.Approved, Vet Approved
BetaxololNicorandil may increase the hypotensive activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Nicorandil.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Nicorandil.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Nicorandil.Approved, Investigational
BisoprololNicorandil may increase the hypotensive activities of Bisoprolol.Approved
BortezomibNicorandil may increase the hypotensive activities of Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Nicorandil.Approved, Investigational
BQ-123Nicorandil may increase the hypotensive activities of BQ-123.Investigational
BretyliumNicorandil may increase the hypotensive activities of Bretylium.Approved
BrimonidineNicorandil may increase the hypotensive activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nicorandil.Experimental
BromocriptineNicorandil may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Nicorandil.Approved
BumetanideNicorandil may increase the hypotensive activities of Bumetanide.Approved
BupivacaineNicorandil may increase the hypotensive activities of Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Nicorandil.Approved
CadralazineCadralazine may increase the hypotensive activities of Nicorandil.Experimental
CafedrineNicorandil may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinNicorandil may increase the hypotensive activities of Canagliflozin.Approved
CandesartanNicorandil may increase the hypotensive activities of Candesartan.Approved
CandoxatrilNicorandil may increase the hyperkalemic activities of Candoxatril.Experimental
CaptoprilNicorandil may increase the hypotensive activities of Captopril.Approved
CarbetocinNicorandil may increase the hypotensive activities of Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nicorandil.Withdrawn
CarteololNicorandil may increase the hypotensive activities of Carteolol.Approved
CarvedilolNicorandil may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Nicorandil.Approved, Investigational
ChlorothiazideNicorandil may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineNicorandil may increase the hypotensive activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneNicorandil may increase the hypotensive activities of Chlorthalidone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Nicorandil.Approved, Investigational
CicletanineNicorandil may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilNicorandil may increase the hypotensive activities of Cilazapril.Approved
CilnidipineNicorandil may increase the hypotensive activities of Cilnidipine.Approved
ClevidipineNicorandil may increase the hypotensive activities of Clevidipine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Nicorandil.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nicorandil.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Nicorandil.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nicorandil.Approved
ClofarabineNicorandil may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClomipramineClomipramine may increase the hypotensive activities of Nicorandil.Approved, Vet Approved
ClonidineNicorandil may increase the hypotensive activities of Clonidine.Approved
CloranololNicorandil may increase the hypotensive activities of Cloranolol.Experimental
ClozapineNicorandil may increase the hypotensive activities of Clozapine.Approved
ConivaptanNicorandil may increase the hypotensive activities of Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Nicorandil.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Nicorandil.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Nicorandil.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nicorandil.Approved
CyclobenzaprineCyclobenzaprine may increase the hypotensive activities of Nicorandil.Approved
CyclopenthiazideNicorandil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Nicorandil.Approved
DapagliflozinNicorandil may increase the hypotensive activities of Dapagliflozin.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Nicorandil.Approved
DelaprilNicorandil may increase the hyperkalemic activities of Delapril.Experimental
DeserpidineNicorandil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneNicorandil may increase the hypotensive activities of Desflurane.Approved
DesipramineDesipramine may increase the hypotensive activities of Nicorandil.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Nicorandil.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Nicorandil.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Nicorandil.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nicorandil.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Nicorandil.Vet Approved
DexmedetomidineNicorandil may increase the hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nicorandil.Approved
DibenzepinDibenzepin may increase the hypotensive activities of Nicorandil.Experimental
DiclofenamideNicorandil may increase the hypotensive activities of Diclofenamide.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Nicorandil.Investigational
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Nicorandil.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Nicorandil.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Nicorandil.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Nicorandil.Investigational
DiltiazemNicorandil may increase the hypotensive activities of Diltiazem.Approved
DinutuximabNicorandil may increase the hypotensive activities of Dinutuximab.Approved
DipyridamoleNicorandil may increase the hypotensive activities of Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nicorandil.Approved
DosulepinDosulepin may increase the hypotensive activities of Nicorandil.Approved
DoxazosinNicorandil may increase the hypotensive activities of Doxazosin.Approved
DoxepinDoxepin may increase the hypotensive activities of Nicorandil.Approved
EfonidipineNicorandil may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinNicorandil may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilNicorandil may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatNicorandil may increase the hyperkalemic activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nicorandil.Experimental
EpanololNicorandil may increase the hypotensive activities of Epanolol.Experimental
EplerenoneNicorandil may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolNicorandil may increase the hypotensive activities of Epoprostenol.Approved
EprosartanNicorandil may increase the hypotensive activities of Eprosartan.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Nicorandil.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Nicorandil.Approved
EsmirtazapineEsmirtazapine may increase the hypotensive activities of Nicorandil.Investigational
EsmololNicorandil may increase the hypotensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Nicorandil.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Nicorandil.Approved
Etacrynic acidNicorandil may increase the hypotensive activities of Etacrynic acid.Approved
FelodipineNicorandil may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamNicorandil may increase the hypotensive activities of Fenoldopam.Approved
Ferulic acidFerulic acid may increase the hypotensive activities of Nicorandil.Experimental
FimasartanNicorandil may increase the hypotensive activities of Fimasartan.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Nicorandil.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nicorandil.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Nicorandil.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nicorandil.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Nicorandil.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Nicorandil.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Nicorandil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Nicorandil.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Nicorandil.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Nicorandil.Approved
ForasartanNicorandil may increase the hyperkalemic activities of Forasartan.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Nicorandil.Approved, Investigational, Withdrawn
FosinoprilNicorandil may increase the hypotensive activities of Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nicorandil.Approved, Vet Approved
FurosemideNicorandil may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Nicorandil.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nicorandil.Approved
GuanazodineNicorandil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Nicorandil.Approved
GuanfacineNicorandil may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorNicorandil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNicorandil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNicorandil may increase the hypotensive activities of Guanoxan.Experimental
HalothaneNicorandil may increase the hypotensive activities of Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nicorandil.Experimental
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Nicorandil.Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Nicorandil.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Nicorandil.Experimental
HydralazineNicorandil may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideNicorandil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Nicorandil.Approved, Vet Approved
HydroflumethiazideNicorandil may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostNicorandil may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilNicorandil may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may increase the hypotensive activities of Nicorandil.Approved
IndapamideNicorandil may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the hypotensive activities of Nicorandil.Withdrawn
IndoraminNicorandil may increase the hypotensive activities of Indoramin.Withdrawn
IprindoleIprindole may increase the hypotensive activities of Nicorandil.Experimental
IproclozideIproclozide may increase the hypotensive activities of Nicorandil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nicorandil.Withdrawn
IrbesartanNicorandil may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidNicorandil may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneNicorandil may increase the hypotensive activities of Isoflurane.Approved, Vet Approved
Isosorbide DinitrateNicorandil may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateNicorandil may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineNicorandil may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineNicorandil may increase the hypotensive activities of Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Nicorandil.Investigational
KetanserinKetanserin may increase the hypotensive activities of Nicorandil.Investigational
LabetalolNicorandil may increase the hypotensive activities of Labetalol.Approved
LacidipineNicorandil may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Nicorandil.Approved, Investigational
LercanidipineNicorandil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololNicorandil may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineNicorandil may increase the hypotensive activities of Levobupivacaine.Approved
LevodopaNicorandil may increase the hypotensive activities of Levodopa.Approved
LevosimendanNicorandil may increase the hypotensive activities of Levosimendan.Approved, Investigational
LinsidomineNicorandil may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilNicorandil may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofepramineLofepramine may increase the hypotensive activities of Nicorandil.Experimental
LofexidineNicorandil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanNicorandil may increase the hypotensive activities of Losartan.Approved
MacitentanNicorandil may increase the hypotensive activities of Macitentan.Approved
ManidipineNicorandil may increase the hypotensive activities of Manidipine.Approved
MannitolNicorandil may increase the hypotensive activities of Mannitol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Nicorandil.Investigational
MebanazineMebanazine may increase the hypotensive activities of Nicorandil.Withdrawn
MecamylamineNicorandil may increase the hypotensive activities of Mecamylamine.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Nicorandil.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Nicorandil.Vet Approved
MethazolamideNicorandil may increase the hypotensive activities of Methazolamide.Approved
MethoserpidineNicorandil may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideNicorandil may increase the hypotensive activities of Methyclothiazide.Approved
MethyldopaNicorandil may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nicorandil.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nicorandil.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nicorandil.Approved, Vet Approved
MetipranololNicorandil may increase the hypotensive activities of Metipranolol.Approved
MetolazoneNicorandil may increase the hypotensive activities of Metolazone.Approved
MetoprololNicorandil may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineNicorandil may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Nicorandil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Nicorandil.Approved
MinoxidilNicorandil may increase the hypotensive activities of Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nicorandil.Investigational
MirtazapineMirtazapine may increase the hypotensive activities of Nicorandil.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nicorandil.Approved
MoexiprilNicorandil may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nicorandil.Approved
MorphineNicorandil may increase the hypotensive activities of Morphine.Approved, Investigational
MoxonidineNicorandil may increase the hypotensive activities of Moxonidine.Approved
MuzolimineNicorandil may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNicorandil may increase the hypotensive activities of Nabilone.Approved, Investigational
NadololNicorandil may increase the hypotensive activities of Nadolol.Approved
NaftopidilNicorandil may increase the hypotensive activities of Naftopidil.Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Nicorandil.Investigational
NebivololNicorandil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideNicorandil may increase the hypotensive activities of Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Nicorandil.Withdrawn
NicardipineNicorandil may increase the hypotensive activities of Nicardipine.Approved
NifedipineNicorandil may increase the hypotensive activities of Nifedipine.Approved
NiguldipineNicorandil may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNicorandil may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNicorandil may increase the hypotensive activities of Nimodipine.Approved
NisoldipineNicorandil may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineNicorandil may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideNicorandil may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinNicorandil may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideNicorandil may increase the hypotensive activities of Nitroprusside.Approved
NortriptylineNortriptyline may increase the hypotensive activities of Nicorandil.Approved
ObinutuzumabNicorandil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nicorandil.Withdrawn
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Nicorandil.Investigational
OlmesartanNicorandil may increase the hypotensive activities of Olmesartan.Approved, Investigational
OmapatrilatNicorandil may increase the hyperkalemic activities of Omapatrilat.Investigational
OpipramolOpipramol may increase the hypotensive activities of Nicorandil.Investigational
OxprenololNicorandil may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelNicorandil may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PapaverineNicorandil may increase the hypotensive activities of Papaverine.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Nicorandil.Approved
PargylinePargyline may increase the hypotensive activities of Nicorandil.Approved
PenbutololNicorandil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Nicorandil.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nicorandil.Approved, Investigational
PerindoprilNicorandil may increase the hypotensive activities of Perindopril.Approved
PhenelzineNicorandil may increase the hypotensive activities of Phenelzine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nicorandil.Withdrawn
PhenoxybenzamineNicorandil may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nicorandil.Withdrawn
PhentolamineNicorandil may increase the hypotensive activities of Phentolamine.Approved
PinacidilPinacidil may increase the hypotensive activities of Nicorandil.Withdrawn
PindololNicorandil may increase the hypotensive activities of Pindolol.Approved
PipamperoneNicorandil may increase the hypotensive activities of Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Nicorandil.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nicorandil.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Nicorandil.Approved
PramipexoleNicorandil may increase the hypotensive activities of Pramipexole.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Nicorandil.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Nicorandil.Investigational
PrazosinNicorandil may increase the hypotensive activities of Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Nicorandil.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nicorandil.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Nicorandil.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nicorandil.Experimental
PropofolNicorandil may increase the hypotensive activities of Propofol.Approved, Investigational, Vet Approved
PropranololNicorandil may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the hypotensive activities of Nicorandil.Approved
QuetiapineNicorandil may increase the hypotensive activities of Quetiapine.Approved
QuinaprilNicorandil may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nicorandil.Approved
RamiprilNicorandil may increase the hypotensive activities of Ramipril.Approved
RasagilineNicorandil may increase the hypotensive activities of Rasagiline.Approved
RemifentanilNicorandil may increase the hypotensive activities of Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nicorandil.Approved
RescinnamineNicorandil may increase the hyperkalemic activities of Rescinnamine.Approved
ReserpineNicorandil may increase the hypotensive activities of Reserpine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Nicorandil.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Nicorandil.Approved
RiociguatNicorandil may increase the hypotensive activities of Riociguat.Approved
RituximabNicorandil may increase the hypotensive activities of Rituximab.Approved
RopiniroleNicorandil may increase the hypotensive activities of Ropinirole.Approved, Investigational
RopivacaineNicorandil may increase the hypotensive activities of Ropivacaine.Approved
RotigotineNicorandil may increase the hypotensive activities of Rotigotine.Approved
SacubitrilNicorandil may increase the hyperkalemic activities of Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nicorandil.Withdrawn
SaprisartanNicorandil may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinNicorandil may increase the hyperkalemic activities of Saralasin.Investigational
SelegilineNicorandil may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SelexipagNicorandil may increase the hypotensive activities of Selexipag.Approved
SevofluraneNicorandil may increase the hypotensive activities of Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nicorandil.Approved, Investigational
SitaxentanNicorandil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteNicorandil may increase the hypotensive activities of Sodium Nitrite.Approved
SotalolNicorandil may increase the hypotensive activities of Sotalol.Approved
SpiraprilNicorandil may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneNicorandil may increase the hypotensive activities of Spironolactone.Approved
StreptokinaseNicorandil may increase the hypotensive activities of Streptokinase.Approved
SufentanilNicorandil may increase the hypotensive activities of Sufentanil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nicorandil.Approved, Investigational
TalinololNicorandil may increase the hypotensive activities of Talinolol.Investigational
TamsulosinNicorandil may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TasosartanNicorandil may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanNicorandil may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilNicorandil may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TerazosinNicorandil may increase the hypotensive activities of Terazosin.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Nicorandil.Approved, Investigational
TetrahydropalmatineNicorandil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideNicorandil may increase the hypotensive activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineNicorandil may increase the hypotensive activities of Theodrenaline.Investigational
ThioridazineNicorandil may increase the hypotensive activities of Thioridazine.Withdrawn
TianeptineTianeptine may increase the hypotensive activities of Nicorandil.Approved
TiboloneTibolone may increase the hypotensive activities of Nicorandil.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Nicorandil.Withdrawn
TimololNicorandil may increase the hypotensive activities of Timolol.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Nicorandil.Approved
TizanidineNicorandil may increase the hypotensive activities of Tizanidine.Approved
TolazolineNicorandil may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeNicorandil may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
TolonidineNicorandil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nicorandil.Approved
TorasemideNicorandil may increase the hypotensive activities of Torasemide.Approved
TrandolaprilNicorandil may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicorandil.Experimental
TranylcypromineNicorandil may increase the hypotensive activities of Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nicorandil.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nicorandil.Approved, Investigational
TretinoinNicorandil may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nicorandil.Approved, Vet Approved
TriamtereneNicorandil may increase the hypotensive activities of Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nicorandil.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Nicorandil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nicorandil.Approved
TrimipramineTrimipramine may increase the hypotensive activities of Nicorandil.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nicorandil.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Nicorandil.Approved
UrapidilUrapidil may increase the hypotensive activities of Nicorandil.Investigational
ValsartanNicorandil may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nicorandil.Approved
VerapamilNicorandil may increase the hypotensive activities of Verapamil.Approved
VincamineNicorandil may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNicorandil may increase the hypotensive activities of Vinpocetine.Investigational
XipamideNicorandil may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Nicorandil.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nicorandil.Approved, Vet Approved
ZofenoprilNicorandil may increase the hyperkalemic activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Kukovetz WR, Holzmann S, Poch G: Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol. 1992;20 Suppl 3:S1-7. [PubMed:1282168]
  2. Russ U, Lange U, Loffler-Walz C, Hambrock A, Quast U: Binding and effect of K ATP channel openers in the absence of Mg2+. Br J Pharmacol. 2003 May;139(2):368-80. [PubMed:12770942]
  3. Yamada M, Kurachi Y: The nucleotide-binding domains of sulfonylurea receptor 2A and 2B play different functional roles in nicorandil-induced activation of ATP-sensitive K+ channels. Mol Pharmacol. 2004 May;65(5):1198-207. [PubMed:15102948]
  4. Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, Nakagawa T: Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. Am J Physiol Renal Physiol. 2012 Aug 1;303(3):F339-49. doi: 10.1152/ajprenal.00158.2012. Epub 2012 May 23. [PubMed:22622455]
  5. Fujiwara T, Angus JA: Analysis of relaxation and repolarization mechanisms of nicorandil in rat mesenteric artery. Br J Pharmacol. 1996 Dec;119(8):1549-56. [PubMed:8982500]
  6. Jahangir A, Terzic A: K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol. 2005 Jul;39(1):99-112. [PubMed:15953614]
  7. Kane GC, Liu XK, Yamada S, Olson TM, Terzic A: Cardiac KATP channels in health and disease. J Mol Cell Cardiol. 2005 Jun;38(6):937-43. Epub 2005 Apr 25. [PubMed:15910878]
  8. Frampton J, Buckley MM, Fitton A: Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 1992 Oct;44(4):625-55. [PubMed:1281076]
  9. Frydman A: Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol. 1992;20 Suppl 3:S34-44. [PubMed:1282174]
  10. 21. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 261). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  11. IKOREL (Nicorandil) Product Information [Link]
  12. UK Medicines and Healthcare products Regulatory Agency (MHRA): Nicorandil Tablets_Scientific Discussion [Link]
External Links
KEGG Drug
D01810
KEGG Compound
C13280
ChemSpider
43240
ChEBI
31905
ChEMBL
CHEMBL284906
Wikipedia
Nicorandil
ATC Codes
C01DX16 — Nicorandil
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (202 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Enrolling by InvitationPreventionRadiation Pneumonitis1
3RecruitingTreatmentMyocardial Infarction (MI)1
4Active Not RecruitingPreventionCoronary Artery Disease / End Stage Renal Disease (ESRD)1
4CompletedTreatmentCoronary Heart Disease (CHD) / Stable Angina (SA)1
4CompletedTreatmentNormal, or Near Normal Coronary Angiography / Slow Coronary Flow / Stable Angina (SA)1
4Not Yet RecruitingTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4RecruitingPreventionCoronary Heart Disease (CHD)1
4RecruitingTreatmentNon-obstructive Coronary Artery Disease1
4Unknown StatusTreatmentDiabetes Mellitus (DM) / Unstable Angina (UA)1
4Unknown StatusTreatmentChronic, stable Angina pectoris1
4WithdrawnTreatmentAngina Pectoris1
Not AvailableCompletedPreventionAcute Myocardial Infarction (AMI) / Congestive Heart Failure (CHF)1
Not AvailableCompletedTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableTerminatedTreatmentHypertensive / Microvascular Angina1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)92-93MSDS
water solubilityPartly miscibleMSDS
Predicted Properties
PropertyValueSource
Water Solubility1.19 mg/mLALOGPS
logP0ALOGPS
logP-0.16ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)13.81ChemAxon
pKa (Strongest Basic)3.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area94.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity49.86 m3·mol-1ChemAxon
Polarizability19.34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0900000000-9439cd529fafd85e86db

Taxonomy

Description
This compound belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Nicotinamides
Alternative Parents
Heteroaromatic compounds / Alkyl nitrates / Secondary carboxylic acid amides / Organic nitro compounds / Organic nitric acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic zwitterions
show 2 more
Substituents
Nicotinamide / Organic nitrate / Alkyl nitrate / Heteroaromatic compound / Carboxamide group / Organic nitric acid or derivatives / Secondary carboxylic acid amide / Organic nitro compound / Organic 1,3-dipolar compound / Allyl-type 1,3-dipolar organic compound
show 11 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridinecarboxamide, nitrate ester (CHEBI:31905)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Transporter activity
Specific Function
Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regul...
Gene Name
ABCC9
Uniprot ID
O60706
Uniprot Name
ATP-binding cassette sub-family C member 9
Molecular Weight
174221.7 Da
References
  1. Russ U, Lange U, Loffler-Walz C, Hambrock A, Quast U: Binding and effect of K ATP channel openers in the absence of Mg2+. Br J Pharmacol. 2003 May;139(2):368-80. [PubMed:12770942]

Drug created on October 21, 2015 18:43 / Updated on October 02, 2017 06:14